NIH-funded research NIH-funded research

Creating better flu vaccines using a new immune booster

Official title: DEVELOPMENT OF VACCINES FOR INFLUENZA USING AN IMMUNO-MODULATOR ADJUVANT AND MULTI-PLATFORM APPROACH

Funded at University of Chicago · NIH-11126498 · Data updated 2026-11-12

This study is looking at a new way to make flu vaccines work better by adding special ingredients that help your immune system respond more effectively, which could lead to fewer side effects and stronger protection against the flu.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Chicago
NIH-funded
Lab location1 site (Chicago, United States)
Project startSeptember 30, 2023
Project endSeptember 29, 2028
Funding year2024
Award (this year)$3,691,826
NIH project number75N93023C00044-P00001-9999-1
Project IDNIH-11126498 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals who are at higher risk for influenza, such as the elderly, young children, and those with compromised immune systems.

Less likely to help

Patients who are not at risk for influenza or those who have contraindications to vaccination may not benefit from this research.

What this research studies

This research focuses on developing a new formulation for flu vaccines that includes an immune-modulating adjuvant to enhance the vaccine's effectiveness. The team aims to customize the immune response to reduce side effects and increase antibody levels, making the vaccine more effective at preventing influenza. They will combine a molecule called Bafetinib with another promising compound, INI-4001, to create a more potent adjuvant system. The research will involve testing these formulations in established vaccine models to ensure their safety and efficacy.

Why it matters

Potential benefit: If successful, this research could lead to more effective flu vaccines with fewer side effects, improving overall public health.

How similar studies have gone: Previous research has shown promise in using immune-modulating adjuvants to enhance vaccine responses, indicating that this approach could be effective.

Where this research is happening

  • University of Chicago
    Chicago, United States
    Active

Researchers

  • Principal investigator: El-Kammash, Bruxanne — University of Chicago
  • Study coordinator: El-Kammash, Bruxanne

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.